Key result
Doxorubicin analogues completely lack cross-resistance in vitro despite being ~5-100-fold less potent than doxorubicin.
Population
Mouse leukemia cells, human uterine sarcoma cells, and human myelocytic cell lines
Comparison
Doxorubicin analogues 2-5 incorporating… vs Doxorubicin
Design
Preclinical
Authors
Loading...
May support testing alkylating anthracyclines in resistant models; leaves open clinical translation from in vitro data.
Effect estimate: 5-100-fold less potent
Alkylating anthracycline analogues may have potential for treating tumors resistant to doxorubicin due to a lack of cross-resistance.
Farquhar et al. (1991) studied Leukemia and uterine sarcoma (in vitro cell lines). Doxorubicin analogues 2-5 vs. Doxorubicin was evaluated on In vitro growth inhibition (5-100-fold less potent). Doxorubicin analogues 2-5 were 5-100-fold less potent than doxorubicin against sensitive cell lines but showed a complete lack of cross-resistance in doxorubicin-resistant cell lines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: